BEARINGPOINT
12.9.2019 09:22:09 CEST | Business Wire | Press release
Almost ten years to the day after the management buyout (MBO) that established the independent, Partner-led management and technology consultancy in 2009, BearingPoint announced that it has launched its Strategy 2025 for even greater success in the decade ahead. Three major ambitions drive the Strategy 2025: to put people in the center, to outperform the market every year and enable European clients to become global leaders, and to be within the top three players in key areas of expertise. Cornerstones of the strategy are to focus on five key areas in consulting for a clear differentiation in the market, to generate new revenue streams with intellectual property, to build critical mass within all practices, to accelerate the growth of BearingPoint’s solutions business, to foster greater collaboration between communities for more innovation, to leverage new business models and ecosystems, and to recruit, develop and retain the best talent.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190912005072/en/
“It’s our firm’s 10th anniversary since we executed our management buyout back in 2009 and created the independent BearingPoint partnership, which I am proud to be part of today. Our Strategy 2025 builds on our existing strengths and puts people first. It outlines clear ambitions for the years ahead and focuses our business and differentiates us in the market,” said Kiumars Hamidian, Managing Partner of BearingPoint. “We are a European success story because of our strong client relationships, our intellectual property, and our people culture, and I am confident that our Strategy 2025 will keep the success going for us and our clients.”
BearingPoint had record revenues of €738 million in 2018 and has grown to more than 4,500 people. The firm said its Strategy 2025 is closely aligned to the market so that growth remains steady and profitable.
Strategy: Focus & Differentiate
BearingPoint said it is building on and further expanding the strengths that differentiate it: the firm’s culture and principles, its management and technology capabilities, its ability to create IP within ecosystems, and its independence and European roots.
“IP creation is something that we already have in our DNA,” said Kiumars, “and we will emphasize this much more. We want to make sure that the great work done on projects is leveraged across the firm from everyone at BearingPoint. Our people-centric approach is characterized by collaboration and communication and reflected in three dimensions: our clients, where we want to focus on the people aspect behind business transformation; our people, where we want to ensure that BearingPoint is the best place to develop and grow; and the communities around us, where we want to make a positive impact.”
BearingPoint structured its operating model into three units. The first unit covers the consulting business with a clear focus on key areas to drive growth across all regions. Earlier this year, BearingPoint established Business Services as a second unit in which it provides IP-driven managed services beyond SaaS and offers business critical services to support the business success of clients. The third business unit provides the software for successful digital transformation and regulatory requirements. It is also designed to explore innovative business models with clients and partners by driving the financing and development of start-ups and leveraging ecosystems.
To create synergies, BearingPoint also combined its practices into three regions: FBLA (France, Belgium, Luxembourg, Africa) led by Eric Falque, GSA (Germany, Switzerland, Austria) led by Iris Grewe, and GROW (Ireland, United Kingdom, Italy, Sweden, Finland, Norway, Netherlands) led by James Rodger. The firm said it seeks to have critical mass in all its practices, which means having at least 100 people in each practice.
The new operating model took effect on September 1.
Management Changes
Matthias Loebich will lead the Markets area of the Consulting unit that comprises all its industry segments. Damien Palacci is leading the Consulting Portfolio, which helps functions of companies with innovative offerings. Patrick Palmgren will lead the newly created business unit covering solutions, M&A activities, and ventures.
Donald Wachs, who leads the Business Services unit, and Damien Palacci have joined the Management Committee of BearingPoint.
About BearingPoint
BearingPoint
is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: The first unit covers the advisory business with a clear focus on five key areas to drive growth across all regions. The second unit provides IP-driven managed services beyond SaaS and offers business critical services to its clients supporting their business success. The third unit provides the software for successful digital transformation and regulatory requirements. It is also designed to explore innovative business models with clients and partners by driving the financing and development of start-ups and leveraging ecosystems.
BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 75 countries, engaging with them to achieve measurable and sustainable success.
For more information, please visit:
Homepage: www.bearingpoint.com
Annual Report: www.bearingpoint.com/en/about-us/annual-report/
LinkedIn: www.linkedin.com/company/bearingpoint
Twitter: @BearingPoint
View source version on businesswire.com: https://www.businesswire.com/news/home/20190912005072/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom